Cannabis businesses intervene in anti-rescheduling lawsuit

Two medical cannabis companies have filed a motion to intervene in litigation aimed at blocking the federal government’s efforts to reschedule marijuana. The businesses argue that a successful legal challenge to the rescheduling reform would cause them significant economic, regulatory, and operational harm. This development highlights the high stakes for the private sector as the federal government navigates the complex legal and administrative process of changing cannabis's status under the Controlled Substances Act.

Two medical cannabis firms have officially moved to intervene in ongoing lawsuits that seek to halt the federal government's progress on marijuana rescheduling under the Trump administration. The companies contend that they have a direct stake in the outcome, asserting that any judicial decision to block the reform would result in immediate negative impacts on their business operations and regulatory standing. This legal maneuver comes as the Drug Enforcement Administration (DEA) prepares for rescheduling hearings, which legal experts Brett Schuman and Adam Horowitz of Goodwin Procter LLP suggest may be structured to ensure the final rule survives inevitable court challenges.

At the state level, significant regulatory shifts are occurring across the country, including Delaware lawmakers overriding Governor Matt Meyer’s veto of a bill that prevents counties from enacting restrictive zoning rules for marijuana businesses. In Georgia, a new law has taken effect that expands the medical cannabis program by adding qualifying conditions, permitting the vaping of flower, and adjusting THC potency limits. Meanwhile, Nebraska Governor Jim Pillen has approved new medical cannabis regulations following the state attorney general's sign-off, and Oregon is moving to combine its medical cannabis and psilocybin oversight into a single regulatory framework.

The hemp sector is also facing legal scrutiny, as Hawaii regulators are currently dealing with a federal lawsuit over newly enforced restrictions on hemp products. On the legislative federal front, a bipartisan group of U.S. Representatives introduced the IBOGAINE Act to codify psychedelics policy, while Pennsylvania’s House minority leader noted that marijuana legalization talks have recently stalled during budget negotiations. Additionally, new scientific research indicates that minor cannabinoids such as cannabigerol (CBG) and cannabichromene (CBC) may induce cell death in lung cancer, and the business sector saw Flowhub launch a new tool allowing clients to integrate artificial intelligence services into their platforms.